Draft amendments to the Medical Device Rules seek to reduce manufacturing licence timelines for Class B, C and D devices to ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene ...
(MENAFN- EIN Presswire) EINPresswire/ -- Electroninks, the leader in metal complex inks for additive manufacturing and advanced semiconductor packaging, today announced the commercial launch timeline ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene ...